GLP1R and type 2 diabetes mellitus: However, the ability of GIP to stimulate insulin secretion eventually declines in T2D individuals, and only GLP-1 action remains intact, which explains the therapeutic efficacy of GLP-1R agonists in T2D patients (Nichols et al., 2020).